Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4242591
Max Phase: Preclinical
Molecular Formula: C34H49N5O8
Molecular Weight: 655.79
Molecule Type: Small molecule
Associated Items:
ID: ALA4242591
Max Phase: Preclinical
Molecular Formula: C34H49N5O8
Molecular Weight: 655.79
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CNCCCNCCCCNCCCNCC(=O)N[C@@H]1c2cc3c(cc2[C@@H](c2cc(OC)c(O)c(OC)c2)[C@H]2C(=O)OC[C@@H]21)OCO3
Standard InChI: InChI=1S/C34H49N5O8/c1-35-8-6-11-36-9-4-5-10-37-12-7-13-38-18-29(40)39-32-23-17-26-25(46-20-47-26)16-22(23)30(31-24(32)19-45-34(31)42)21-14-27(43-2)33(41)28(15-21)44-3/h14-17,24,30-32,35-38,41H,4-13,18-20H2,1-3H3,(H,39,40)/t24-,30+,31-,32+/m0/s1
Standard InChI Key: KBAIJCVHIHPKQR-YZCUKXFTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 655.79 | Molecular Weight (Monoisotopic): 655.3581 | AlogP: 1.78 | #Rotatable Bonds: 19 |
Polar Surface Area: 160.67 | Molecular Species: BASE | HBA: 12 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 13 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.32 | CX Basic pKa: 10.81 | CX LogP: -1.04 | CX LogD: -6.26 |
Aromatic Rings: 2 | Heavy Atoms: 47 | QED Weighted: 0.10 | Np Likeness Score: 0.80 |
1. Oviatt AA, Kuriappan JA, Minniti E, Vann KR, Onuorah P, Minarini A, De Vivo M, Osheroff N.. (2018) Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ., 28 (17): [PMID:30006062] [10.1016/j.bmcl.2018.07.010] |
Source(1):